So I can only take from that statement that the results the MSB have in CHF and CLBP ( probably COVID ARDS ) are multiples better than those that Novartis got approval on. Astonishing P values on low numbers.
This is why we holders are pumped with excitement.
Is it not time to catch the train?
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-266
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.020(2.02%) |
Mkt cap ! $1.158B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $994.2K | 991.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14277 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 102730 | 9 |
View Market Depth
| Last trade - 11.02am 15/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |